Business Wire

Sysdig Usage Report Finds Shifting Container Security Left is Not Enough

Share

Sysdig, Inc., the secure DevOps leader, today announced findings from its Sysdig 2021 Container Security and Usage Report. While usage reveals organizations are shifting left by scanning images during the build phase, DevOps teams are still leaving their environments open to attack. The report also looks at trends, finding a 310 percent growth in container density since 2017.

The fourth annual report reveals how global Sysdig customers of all sizes and across industries are using and securing container environments. This real-world, real-time data provides insight into usage of the nearly one billion containers Sysdig customers run yearly, including security risks, container utilization, and services used. Read the Sysdig 2021 Container Security and Usage blog.

Among its findings, the report states that while 74 percent of customers are scanning before deployment, still more than half (58 percent) of containers are running as root. There are some containers that should run as root—security and system daemons for example—but this is a small portion of total containers. These risky configurations leave easy access to potentially compromise the system and access sensitive data. This finding stresses the need for security throughout the lifecycle of a container image—fixing vulnerabilities is not enough.

Highlights From the Report

Container density grows 170% since 2018

Over the past three years, the median number of containers-per-host more than doubled from 15 in 2018 to 41 today, indicating a growth in efficiency and a shift in cost savings as containers mature. This reveals a continued focus on optimization.

Prometheus continues to grow, 35% YoY

Open source adoption is broader than just Kubernetes as organizations are shifting toward Prometheus as the standard approach to monitoring container environments. The use of Prometheus metrics among Sysdig customers grew 35 percent year-over-year.

Docker down, containerd and CRI-O up 4X

In 2017, Docker represented 99 percent of containers in use at that time. Today, that number has fallen to 50 percent, down from 79 percent in October 2019. While Docker revolutionized containers, organizations are rapidly switching to newer runtimes like containerd and CRI-O.

21% of containers live less than 10 seconds

The ephemeral nature of containers is a unique efficiency advantage, yet it can be a challenge in managing issues around security, health, and performance. The short life of containers reaffirms the need for container-specific tools for security and monitoring. For example, organizations need metric collection with intervals of less than 10 seconds and a detailed record of what occurred when the container was alive.

“With the high-profile breaches we are seeing and the accelerated adoption of containers in production, the container security risk is now on the radar of CISOs. Across millions of containers that we have studied, it’s clear that organizations are shifting security left, but they are neglecting critical best practices,” said Suresh Vasudevan, chief executive officer of Sysdig. “Container security has to span the entire software development lifecycle. Until organizations fix risky configurations, protect their runtime environments, and invest in container forensics, we will see an increase in container security breaches. I expect we will see several high-impact breaches before we release our next report.”

Other Interesting Findings

  • Falco, the open source runtime project for cloud-native environments created by Sysdig and donated to the CNCF, has seen a 300 percent increase in Docker Hub downloads over the last year.
  • The use of golang increased to 66 percent, a 470 percent jump since last year.
  • 63 percent of container images are replaced within two weeks or less, signifying a more frequent code deployment rate.

Learn More About this Report

About Sysdig

Sysdig is driving the secure DevOps movement, empowering organizations to confidently secure containers, Kubernetes, and cloud services. With the Sysdig Secure DevOps Platform, cloud teams secure the build pipeline, detect and respond to runtime threats, continuously validate compliance, and monitor and troubleshoot cloud infrastructure and services. Sysdig is a SaaS platform, built on an open source stack that includes Falco and sysdig OSS, the open standards for runtime threat detection and response. Hundreds of companies rely on Sysdig for container and Kubernetes security and visibility. Learn more at www.sysdig.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Amanda McKinney Smith
(703) 473-4051
amanda.smith@sysdig.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye